Results 161 to 170 of about 3,220 (195)
Some of the next articles are maybe not open access.
Analysis of PBPK Models for Risk Characterization
Annals of the New York Academy of Sciences, 1999Abstract: Adoption of a Bayesian framework for risk characterization permits the seamless integration of different kinds of information available in order to choose and parameterize risk models. It also becomes easy to disentangle uncertainty from variability, through hierarchical statistical modeling.
openaire +3 more sources
Windows based general PBPK/PD modeling software
Computers in Biology and Medicine, 2008A physiologically based pharmacokinetic (PBPK) model and program (called PostNatal) was developed which focuses on postnatal growth. Algorithms defining organ/tissue growth curves from birth through adulthood for male and female humans, dogs, rats, and mice are utilized to calculate the appropriate weight and blood flow for the internal organs/tissues.
Richard H, Luecke +5 more
openaire +2 more sources
PBPK modeling of complex hydrocarbon mixtures: gasoline
Environmental Toxicology and Pharmacology, 2004Petroleum hydrocarbon mixtures such as gasoline, diesel fuel, aviation fuel, and asphalt liquids typically contain hundreds of compounds. These compounds include aliphatic and aromatic hydrocarbons within a specific molecular weight range and sometimes lesser amounts of additives, and often exhibit qualitatively similar pharmacokinetic (PK) and ...
James E, Dennison +4 more
openaire +2 more sources
Physiologically Based Pharmacokinetic (PBPK) Modeling in Children
Clinical Pharmacology & Therapeutics, 2012This review summarizes the present status of physiologically based pharmacokinetic (PBPK) modeling and simulation (M&S) and its application in support of pediatric drug research. We address the reasons that PBPK is suited to the current needs of pediatric drug development and pharmacotherapy in light of the evolution in pediatric PBPK methodologies and
J S, Barrett +3 more
openaire +2 more sources
PBPK Modeling Advances Understanding of D4 Pharmacokinetics
Toxicological Sciences, 2003The article highlighted in this issue is Physiological Modeling of Inhalation Kinetics of Octamethylcyclotetrasiloxane in Humans during Rest and Exercise, by Micaela B. Reddy, Melvin E. Andersen, Paul E. Morrow, Ivan D. Dobrev, Sudarsanan Varaprath, Kathleen P. Plotzke, and Mark J. Utell (pp. 43-56).
openaire +2 more sources
PBPK modeling of irbesartan: incorporation of hepatic uptake
Biopharmaceutics & Drug Disposition, 2015AbstractPhysiological based pharmacokinetic (PBPK) modeling is now commonly used in drug development to integrate human or animal physiological data in order to predict pharmacokinetic profiles. The aim of this work was to construct and refine a PBPK model of irbesartan taking into account its active uptake via OATP1B1/B3 in order to predict more ...
Helene, Chapy +5 more
openaire +2 more sources
Physiologically Based Pharmacokinetic (PBPK) Modeling of Pharmaceutical Nanoparticles
The AAPS Journal, 2016With the great interests in the discovery and development of drug products containing nanoparticles, there is a great demand of quantitative tools for assessing quality, safety, and efficacy of these products. Physiologically based pharmacokinetic (PBPK) modeling and simulation approaches provide excellent tools for describing and predicting in vivo ...
Min, Li +3 more
openaire +2 more sources
A PBPK model for midazolam in four avian species
Journal of Veterinary Pharmacology and Therapeutics, 2009A physiologically based pharmacokinetic (PBPK) model was developed for midazolam in the chicken and extended to three other species. Physiological parameters included organ weights obtained from 10 birds of each species and blood flows obtained from the literature. Partition coefficients for midazolam in tissues vs.
K A, Cortright +2 more
openaire +2 more sources
Assessing interindividual variability by Bayesian-PBPK modeling
Drug Discovery Today: Disease Models, 2016The description of interindividual variability and the ADME-related sources of such variability (ADME: absorption, distribution, metabolization, excretion) is an essential element in clinical drug development to identify potentially relevant subgroups of non-responders or high-risk patients.
Markus Krauss, Andreas Schuppert
openaire +1 more source
Chlorpyrifos PBPK/PD model for multiple routes of exposure
Xenobiotica, 20141. Chlorpyrifos (CPF) is an important pesticide used to control crop insects. Human Exposures to CPF will occur primarily through oral exposure to residues on foods. A physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model has been developed that describes the relationship between oral, dermal and inhalation doses of CPF and key events ...
Torka S, Poet +3 more
openaire +2 more sources